Keywords:
CRISPR-Cas Systems; cell lines; tumours; immunotherapy; genetics; neoplasms; immunology; therapy; aednosine A2A; chimeric antigen; T-lymphocytes
Keywords:
CRISPR-Cas Systems; cell lines; tumours; immunotherapy; genetics; neoplasms; immunology; therapy; aednosine A2A; chimeric antigen; T-lymphocytes